Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Evaluation of the Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of < 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Inclusion criteria

• Patients of pediatric age up to 22 years included at the time of molecular analysis
• Histological carcinological diagnosis performed at HUS
• Carcinological follow-up performed at HUS
• Patients with a solid tumor of unfavorable prognosis, refractory or in relapse
• Molecular analysis performed on tumor or blood samples
• Adult patients who do not object to the re-use of their personal data for medical research purposes
• Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes.

Criteria for non-inclusion

• Molecular biology results not usable due to poor sample quality or insufficient genetic material
• Patients who have expressed their opposition to participate in the study
• Parental authority holders who have expressed their opposition to participate in the study